Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDGlobeNewsWire • 04/15/25
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug ImportsInvestors Business Daily • 04/09/25
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisGlobeNewsWire • 04/08/25
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesZacks Investment Research • 04/03/25
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesGlobeNewsWire • 04/03/25
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesZacks Investment Research • 04/01/25
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitorsGlobeNewsWire • 03/28/25
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDGlobeNewsWire • 03/28/25
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)Zacks Investment Research • 03/26/25
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDAGlobeNewsWire • 03/26/25
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug TolebrutinibZacks Investment Research • 03/25/25
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosisGlobeNewsWire • 03/25/25
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease DrugZacks Investment Research • 03/20/25
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineGlobeNewsWire • 03/20/25
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu seasonPRNewsWire • 03/14/25
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?Benzinga • 03/12/25